Table 6

Univariate analysis of SGRQ-improved versus non-improved participants with airway obstruction defined by FEV1/FVC<0.7

Improved (n=31)Non-improved (n=45)p Value
Male sex21 (67.7)34 (75.6)0.456
Age, year66.6±9.767.8±9.70.597
Cigarettes smoked daily, N23.3±12.422.4±12.60.758
Duration of smoking, year45.4±12.046.3±11.50.733
Brinkman Index1072.7±675.9994.0±525.80.570
TDS score8.0±1.57.2±1.70.040
Baseline exhaled CO, ppm11.6±7.010.5±8.40.529
Changes in exhaled CO, ppm−8.6±7.9−5.0±7.00.041
Body mass index, kg/m223.4±3.521.8±3.50.639
Baseline FEV1, % predicted52.0±19.860.3±17.80.061
Baseline FVC, % predicted73.6±21.581.5±17.40.085
FEV1/FVC, %56.0±11.658.9±9.40.223
Changes in FEV1, L0.13±0.280.08±0.320.513
Treated by varenicline13 (41.9)20 (44.4)0.828
Quitter17 (54.8)33 (73.3)0.096
Mental disorder6 (19.4)10 (22.2)0.762
Diabetes mellitus3 (9.7)5 (11.1)0.841
Cardiovascular disease8 (25.8)6 (13.3)0.172
COPD17 (54.8)16 (35.6)0.095
Bronchial asthma6 (19.4)7 (15.6)0.667
Cancer4 (12.9)6 (13.3)0.957
  • Data are presented as number (%) or mean±SD.

  • COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SGRQ, St. George's Respiratory Questionnaire; TDS, Tobacco Dependence Screener test.